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Abstract
Background: Hepatitis B virus (HBV) infection is a significant public health problem that may lead
to chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC). Approximately 30% of the
world's population has been infected with HBV and approximately 350 million (5–6%) are
persistent carriers. More than 120 million Chinese are infected with HBV. The role of host genetic
factors and their interactions with environmental factors leading to chronic HBV infection and its
complications are not well understood. We believe that a better understanding of these factors
and interactions will lead to more effective diagnostic and therapeutic options.
Methods/Design: This is a population-based, case-control study protocol to enroll 2200 Han
Chinese from medical centers in northern and western China. Adult subjects in the following
groups are being enrolled: healthy donors (n = 200), HBV infected persons achieving virus
clearance (n = 400), asymptomatic HBV persistent carriers (n = 400), chronic hepatitis B cases (n
= 400), decompensated liver cirrhosis with HBV infection cases (n = 400), and hepatocellular
carcinoma with HBV infection cases (n = 400). In addition, for haplotype inference and quality
control of sample handling and genotyping results, children of 1000 cases will be asked to provide
a buccal sample for DNA extraction. With the exception of adult patients presenting with liver
cirrhosis or HCC, all other cases and controls will be 40 years or older at enrollment. A
questionnaire is being administered to capture dietary and environmental risk factors. Both
candidate-gene and genome-wide association approaches will be used to assess the role of single
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genetic factors and higher order interactions with other genetic or environmental factors in HBV
diseases.
Conclusion: This study is designed and powered to detect single gene effects as well as gene-gene
and environmental-gene interactions. The identification of allelic polymorphisms in genes involved
in the pathway leading to chronic viral infection, liver cirrhosis and, ultimately, hepatocellular
carcinoma would provide insights to those factors leading to HBV replication, liver inflammation,
fibrosis, and the carcinogenic process. An understanding of the contribution of host genetic factors
and their interactions may inform public health policy, improve diagnostics and clinical management,
and provide targets for drug development.
Background
Hepatitis B virus (HBV) infection is a significant public
health problem that may lead to chronic liver disease, cir-
rhosis, and hepatocellular carcinoma (HCC) [1]. Approx-
imately 30% of the world's population has been infected
with HBV and approximately 350 million (5–6%) are per-
sistent carriers. Infants infected perinatally by vertical
transmission from e antigen positive mothers have a 90%
risk of becoming persistent carriers. Approximately 90%
of preschool children infected with HBV will fail to
achieve clearance and develop persistent HBV infection.
For adults, the majority of HBV-infected individuals
achieve clearance with only 5–10% becoming persistent
carriers of HBV. HBV accounts for 80% of all liver cancer
and is an important carcinogen [2]. Of individuals persist-
ently infected with HBV, 10–30% will develop liver cir-
rhosis (LC) and HCC [2]. These highly variable outcomes
in both clearance rates and disease outcomes in persist-
ently infected individuals cannot be fully explained by dif-
ferences in viral or environmental factors. Thus,
differences in host genetic factors may affect hepatitis B
natural history.
Viral factors that may influence HBV outcomes include
HBV DNA levels, HBV genotypes, HBV genetic variants,
and co-infection with other hepatitis viruses. HBV DNA
levels are correlated with T-cell hyporesponsiveness to
HBV antigens [3] and are a risk predictor for HCC devel-
opment [4,5]. Treatment with lamivudine [6] and inter-
feron-alpha (IFN-α) [7,8] decreases viral load [3] and
reduces occurrence of HCC. Of the eight HBV genotypes
(A-H), HBV-A has been associated with persistence [9],
HBV-C with severe liver disease [10,11], and HBV-B with
more benign disease [11]; however, HBV-B was found to
be a predictor for HCC [10]. A double mutation in the
base core promoter of the HBV genome reported to aggra-
vate chronic hepatitis is more frequent in HBV-C isolates
than in HBV-B isolates [12]. Amino acid replacements in
the "α" determinant of the HBs protein, the proposed
coformational epitope essential for recognition and neu-
tralization by anti-HBs antibodies, have been reported
[13,14]. A precore stop codon mutation (1896G to A)
[15] and two mutations within the core promoter region
(1762A to T and 1764G to A) [16,17] have been associ-
ated with fulminant hepatitis B. Both variants show a
defect in hepatitis e antigen (HBeAg) expression [18,19],
which may modify the immune response of the host
[20,21]. However, in many cases of fulminant hepatitis B,
particularly those from nonendemic areas [22,23], neither
of these mutations was observed. These investigations
indicate that HBV viral burden, genotype, and genetic pol-
ymorphism are important contributors to the natural his-
tory of HBV disease and may explain, in part, the observed
heterogeneity in outcomes of infection.
Environmental factors are clearly implicated in HBV
pathogenesis. Alcohol and aflatoxin are two important
factors that affect the progression of chronic hepatitis B.
Alcohol consumption increases the severity of liver dis-
ease [24,25] and increases the risk of developing liver
decompensation from cirrhosis [26]. Patients with
chronic hepatitis B exposure to aflatoxins are at an
increased risk of HCC [27], especially in the Fusui County
of Guangxi Zhuan Autonomous Region [27,28] and the
Qidong district of Jiangsu Province [29,30] in China,
where the highest rates of HCC are found and aflatoxins
levels are high in many local foods and grains. In Fusui
County of China, the rate of HCC is 120 per 100,000 per-
sons/year among men [31], a rate 35 times higher than
that in United States. The tumor suppressor gene p53
294ser mutation is a 'hotspot' mutation in HCC from
patients in regions with dietary aflatoxins exposure
[32,33].
The role of host genetic factors on HBV persistence and
pathogenesis is less well understood. CD4+ T cell prolifer-
ative responses in acute HBV infection are significantly
more vigorous than those seen in persistent HBV infec-
tion, suggesting that MHC class II polymorphisms influ-
ence susceptibility to persistent infection. Several MHC
class II alleles have been identified in association with
clearance or persistence of HBV infection [34-37]. Poly-
clonal and multispecific CD8+ T cells are readily detecta-
ble in the peripheral blood of patients with acute HBV
infection or HBV clearance, but are rarely detectable in
patients with persistent HBV infection. This suggests thatBMC Infectious Diseases 2008, 8:1 http://www.biomedcentral.com/1471-2334/8/1
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HLA alleles may be key determinants of HBV clearance;
however, there have been few comprehensive studies of
HLA class I alleles and the results for class II alleles have
been inconsistent [34-37]. In a comprehensive case-con-
trol study, Thio et al recently showed that the class I allele,
A*301 and class II allele DRB1*1302 are associated with
clearance and two class I alleles, B*08 and B*44, are asso-
ciated with persistence, thus confirming an earlier studies
implicating DRB1*1302 in HBV clearance [38].
Cytokines, chemokines and their receptors may also have
a role in HBV persistence and disease. A number of asso-
ciations with cytokines have been reported. Tumor necro-
sis factor (TNF)-α was associated with HBV persistence
[39] and HCC [40,41]. Interleukin(IL)-10 was associated
with high risk of HCC [42,43]. Genetic associations have
also been observed for the mannose binding protein
(MBP) [44-47] and the vitamin receptor D [48] with per-
sistence, and hormonal markers with HCC [49,50]. Many
of the genetic associations have been inconsistent among
studies, possibly due to population substructure, small
sample size, or differences in study design, or have not yet
been replicated in duplicate studies.
These studies strongly suggest that genetic factors influ-
ence HBV disease; however, these influences are likely
interactive with viral and environmental factors. The pri-
mary objective of this study is to localize and identify
genes that influence HBV persistence and adverse out-
comes of HBV infection by employing a population-based
genetic association strategy with both candidate-gene and
genome-wide association approaches. We have therefore
implemented a HBV genetic study powered to detect
genetic factors and their interactions in individuals repre-
senting the different stages of HBV disease: clearance, per-
sistent infection, chronic hepatitis B, cirrhosis, and HCC,
as well as normal healthy controls from the Han Chinese
population in the north and west region of China (Table
1). Specific hypotheses and comparison groups are listed
in Table 2.
Methods/Design
Recruitment sites
This study is a population-based, multicenter case-control
study under a single protocol for the investigation of
genetic and environmental predictors of HBV susceptibil-
ity and diseases associated with chronic HBV infection. To
meet recruitment goals twelve hospitals (Table 1) are
enrolling patients following protocol criteria for inclusion
and exclusion. The repository, central database and coor-
dinating center is located at Peking University First Hospi-
tal, Beijing. Blood samples are processed at local sites for
isolation of peripheral blood mononuclear cells, plasma,
serum and clot. All laboratory, pathology, and imaging
will be done at the participating centers.
Human subjects and enrollment criteria
Human subjects
Potential participants will be invited to fill in a pre-entry
questionnaire for eligibility. All cases are interviewed as
out- or in-patients at the participating hospitals by trained
interviewers using a standard questionnaire to capture
behaviors, environmental exposures, and family history
related to hepatitis B infection. To reduce population het-
Table 2: Genetic hypothesis comparison groups.
HBV Persistence
I. Persistent infection vs. 
clearance (B+C vs. A)
Disease Category 1 Asymptomatic HBV 
infection
B group
Chromic Hepatitis B C group
Disease Category 2 Clearance A group
HBV Progression
II. Chronic Hepatitis B 
(C vs. D+E)
Disease Category 1 Chronic Hepatitis B C group
Disease Category 2 Decompensated Cirrhosis D group
Hepatocellular carcinoma E group
III. Cirrhosis (D vs. C)
Disease Category 1 Decompensated Cirrhosis D group
Disease Category 2 Chronic Hepatitis B C group
IV. Hepatocellular 
Carcinoma (E vs. C)
Disease Category 1 Hepatocellular carcinoma E group
Disease Category 2 Chronic Hepatitis B C group
V. Asymptomatic HBV 
Infection (B vs. C)
Disease Category 1 Asymptomatic HBV 
Infection
B group
Disease Category 2 Chronic Hepatitis B C group
Table 1: Participating hospitals or medical centers, city and 
province.
Hospital City and Province
Peking University First Hospital Beijing
Peking University Second Hospital Beijing
Peking Ditan Hospital Beijing
Beijing Military General Hospital Beijing
Beijing Institute of Tumor Prevention 
and Therapy
Beijing
Peking Union Medical College Beijing
Inner Mongolia Medical College Hohhot, Inner Mongolia
Xinjiang Medical University Urumoqi, Xinjiang Province
Qinhuangdao No. 3 Hospital Qinhuangdao, Hebei Province
China Medical University Shenyang, Liaoning Province
Shanxi Medical University Taiyuan, Shanxi Province
Xuzhou No. 3 Hospital Xuzhou, Jiangshu ProvinceBMC Infectious Diseases 2008, 8:1 http://www.biomedcentral.com/1471-2334/8/1
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erogeneity and confounding by dietary aflatoxin expo-
sure, only cases and controls of the Han ethnicity born
and residing in north and west of China are eligible for
enrollment. Local internal review board approvals from
participating hospitals have been obtained and informed
consent from each participant is required for study enroll-
ment.
A total of 3200–3400 subjects will be enrolled in the study
with at least 400 persons per group for HBV clearance,
chronic asymptomatic HBV infection, chronic sympto-
matic infection, decompensated liver cirrhosis, and HCC.
In addition, adult children or both parents of probands
are invited to provide a buccal sample for DNA isolation;
this will be used for haplotype inference and quality con-
trol of sample handling and genotyping results. Normal
healthy donor controls are enrolled from local blood
banks and will be negative by serological testing for HCV,
HDV, and HBV. With the exception of cirrhosis and HCC
cases whom are enrolled at any age of diagnosis, all cases
and controls, except for those with cirrhosis or HCC, will
be over 40 years of age at enrollment to provide adequate
time for symptoms to manifest and to reduce probability
of HBV vaccination exposure. Only probands reporting at
least one parent or sibling with chronic HBV infection
(HBsAg+) will be enrolled to increase the probability of
HBV infection exposure at birth or early childhood.
In addition, for haplotype inference and for quality con-
trol of sample handling and genotyping results, children
of 1000 cases will be asked to provide a buccal sample for
DNA extraction.
Inclusion and exclusion criteria
The diagnostic criteria for study inclusion are listed in
Table 3. Approached persons other than children or par-
ents of probands are excluded from enrollment if they
meet one or more of the exclusion criteria: 1) evidence of
past or current infection by HCV or HDV; 2) birth or
greater than 6 month residency in Fusui County, Guangxi
Province; 3) age less than 40 for all cases and controls
except HCC and cirrhosis cases; 4) other systemic disease
not related to HBV infection; 5) one or more parents or
grandparents not of Han ethnicity; or 6) with other hepa-
titis virus infection.
Case definitions of HBV infection and outcomes are in
accordance with the criteria issued by the Association of
Infectious Diseases and Parasites Diseases of China in
2000 (Table 3) [51].
Assay methods
Quantitative markers of liver function
The normal ranges for the following markers of liver func-
tion are: alanine aminotransferase (ALT) (0–40 IU/L);
aspartate aminotransferase (AST) (0–45 IU/L); bilirubin
(0–20  μmol/L); albumin 35–55 g/L; alpha-fetoprotein
(AFP) (0–20 ng/mL).
Assays for hepatitis virus markers
Serum hepatitis B surface antigen (HBsAg), anti-HBs and
anti-HCV antibody will be determined by the Ortho/
Chemi-luminescent assay (Johnson and Johnson Co.,
USA). Hepatitis B e antigen and anti-HBe will be deter-
mined by the enzyme-linked immunosorbent assay using
commercially available kits (AxSYM, Abbott, USA). HBV
DNA will be quantified using real-time polymerase chain
reaction with lower limit of detection of 1000 copies/mL.
Anti-HAV IgM antibody and anti-HEV antibody will be
determined by commercially ELISA kits in China. HDV
antigen (HDAg) and anti-HDV antibody will also be
determined by ELISA method.
Phenotype category definitions (Table 3)
Clearance
Clearance is defined as a seropositive tests for antibodies
against HBV surface antigen (anti-HBs) and against HBV
core antigen (anti-HBc) without the presence of HBs anti-
gen (HBsAg) at the time of study entry and to have no self-
reported and/or hospital record of chronic HBV infection.
Asymptomatic Chronic HBV infection
Asymptomatic chronic infection is defined by two posi-
tive tests for HBsAg and antibodies to HBcAg at least 6
months apart. Alanine aminotransferase (ALT) and aspar-
tate aminotransferase (AST) are measured by local hospi-
tal laboratories. Only individuals with normal values for
ALT and AST at two timepoints separated by 12 or more
months meet criteria for asymptomatic chronic infection.
Laboratory measurements are obtained at study entry and
from medical record review.
Chronic Hepatitis B
Chronic HBV infection is defined by two positive tests for
HBsAg and antibodies to HBcAg at least 6 months apart
and ALT and/or AST levels greater than 60 IU/L for the
testing hospital before or at enrollment. To rule out con-
founding by co-infection with HCV or HDV, participants
must be seronegative for anti-HCV, HDV antigen or anti-
HDVAg, and have no detectable HCV RNA.
Decompensated liver cirrhosis
HBV-related decompensated liver cirrhosis is defined by
liver cirrhosis in patients with persistent HBV infection
and at least one of the following: 1) severe gastroesopha-
geal varication (3°); 2) history of bleeding or current
bleeding; 3) ascites or edema; 4) encephalopathy; 5)
serum albumin < 35 g/L, total bilirubin >35 umol/L.BMC Infectious Diseases 2008, 8:1 http://www.biomedcentral.com/1471-2334/8/1
Page 5 of 9
(page number not for citation purposes)
Primary heptocellular carcinoma
HBV-related HCC is defined by at least one of the follow-
ing: 1) liver biopsy; or 2) elevated AFP levels and sono-
graphic, CT, or MRI evidence.
Environmental risk factors
A single questionnaire is used at all enrollment sites and
is administered by trained health care professionals. The
instrument was developed to record self-report of risk fac-
tors for HBV transmission: family history of HBV infec-
tion, HBV-infected sexual partner(s), nosocomial
exposure by invasive dental or surgical procedures, and
tattooing. Past and current smoking, alcohol ingestion
and exposure to dietary aflatoxin B are also captured.
Demographic information will include gender, birth-date,
birthplace, and past and current residency.
Table 3: Number of subjects and inclusion criteria
Group A: Clearance cases (n = 400)
1. Anti-HBs and anti-HBc positive or anti-HBs positive and no vaccination history;
2. HBV-DNA negative, HDAg negative and/or anti-HDV negative;
3. Anti HCV and HCV RNA negative;
4. ALT <40 IU/L and AST <45 IU/L at enrollment; and
5. Age ≥ 40.
Group B: Persistent asymptomatic HBV infection (n = 400) 
1. HBsAg and anti-HBc positive;
2. Anti-HCV and HCV RNA negative;
3. Anti-HDV and/or HDAg negative;
4. At least 1 sibling or parent HBsAg positive;
5 ALT <40 and AST <45 IU/L for at least 5 years;
6. No clinical symptoms of hepatitis;
7. No clinical liver cirrhosis; and
8. Age ≥ 40.
Group C: Chronic hepatitis B (n = 400)
1. HBsAg and anti-HBc positive for at least 6 months;
2. Anti-HCV and HCV RNA negative;
3. Anti-HDV and/or HDAg negative;
4. At least 1 sibling or parent HBsAg positive;
5. ALT and/or AST levels greater than 2 times upper limits of normal range for testing hospital before or current;
6. No clinical evidence of liver cirrhosis;
7. Age ≥ 40.
Group D: HBV-related decompensated liver cirrhosis (n = 400)
1. HBsAg and anti-HBc positive;
2. Anti-HCV and HCV RNA positive;
3. Anti-HDV and/or HDAg negative; and
4. Liver cirrhosis with clinical presentation of gastroesophageal varication (3°) or a history of bleeding, or ascites, or edema, or encephalopathy, or 
serum Albumin < 35 g/L, total bilirubin > 35 μmol/L.
Group E: HBV-related hepatocellular carcinoma (n = 400)
1. HBsAg and anti-HBc positive;
2. Anti-HCV and HCV RNA positive;
3. Anti-HDV and/or HDAg negative; and
4. HCC confirmed by biopsy or elevated AFP and sonography or CT or MRI.
Group F: Hypernormal control group (n = 200)
1. Anti-HBs, HBsAg and anti-HBc negative and no HB vaccination history;
2. Anti-HCV and HCV RNA;
3. Anti-HDV and/or HDAg negative;
4. ALT <40 and AST <45 IU/L; and
5. Age ≥ 40.BMC Infectious Diseases 2008, 8:1 http://www.biomedcentral.com/1471-2334/8/1
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Sample size criteria
We determined that 400 each cases and controls would
provide >90% power to detect moderate associations (OR
≥ 2) at α ≤ 0.05 for factors having a 10% frequency or
greater (Table 4).
Genetic strategy
This is a population-based study that will use both candi-
date-gene and genome- wide association (GWA)
approaches to identify genetic factors associated with
clearance, persistence, cirrhosis, and HCC. A population
donor control group will be used for allele frequency
determination in local populations and first-degree fam-
ily members will be used for haplotype determination
and quality control of sample handling and genotyping.
Selection of candidates will include genes encoding pro-
teins that metabolize or transport toxins biotransforma-
tion genes, immune response genes (ligands and receptors
for cytokines and chemokines, HLA, and KIR), DNA
repair genes, tumor suppressor genes, genes encoding pro-
teins used by HBV for replication, and other genes
involved in the oncogenic pathways. Haplotype tagging
SNPs and SNPs with known or putative function will be
selected.
Statistics
Tests for Hardy-Weinberg equilibrium will be tested sepa-
rately for cases and controls. Genotypic analyses will con-
sider allele, dominant, recessive and additive genetic
models. Haplotypes will be inferred using a Bayesian
method (PHASE). Cases and controls will be group-
matched and analyses will be stratified by collection site,
sex, and adjusted for alcohol, smoking, diet, HBV viral lev-
els and HBV genotype. Odds ratios will be determined
using unadjusted and adjusted logistic regression analyses
and the significance of association will be determined
using 2-tailed Mantel-Haenszel trend test for additive
models and the Chi-square or Fisher-exact test for allele,
dominant and recessive genetic models.
Discussion
Chronic HBV infection is a major contributor to morbid-
ity and mortality worldwide despite the availability of effi-
cient vaccines and vaccination programs in China and
elsewhere [52]. The underlying environment factors con-
tributing to HBV chronic infection are well known, but
the pathophysiology of HBV-related cirrhosis and HCC
are incompletely understood and the interactions
between environmental and genetic factors have not been
systematically explored. The susceptibility genes leading
to chronic infection and subsequent disease likely affect
many different pathways ranging from mediators of
immune response and inflammation to oncogenic path-
ways. These genes may have main effects or be interactive
with environmental or other genetic factors. The discovery
of either main effect or interactive genes will help us to
better understand HBV pathogenesis. This study is unique
in that we have enrolled participants representing the
spectrum of HBV exposure and pathogenesis ranging from
spontaneous clearance to persistent infection leading to
decompensated cirrhosis and liver cancer in a population
from north and west of China (Table 1).
Heterogeneity in HBV pathogenesis and disease outcomes
may be influenced by environmental factors that differ
over time or geographically. In an effort to reduce bias due
to changes in preventive medicine and public health
measures that have impacted nutrition, HBV exposure,
vaccination, and medical treatment, this study is limited
to persons greater than 40 years old, except for cirrhosis
and HCC. A particular problem with many genetic studies
is population substructure where cases are genetically dif-
ferent from controls. If undetected, population substruc-
ture may lead to false discovery, even within populations
considered to be genetically homogeneous [53-56]. We
have attempted to minimize substructure by enrolling
only Han Chinese whose primary residence is in north
and west of China.
The strongest association with HCC is dietary aflatoxin
exposure, a known carcinogen with high levels docu-
mented in southeast China, and particularly in Fusui
County, Guangxi Province, in the Qidong district of
Jiangsu Province. After 1986, food-handling practices
were modified to eliminate aflatoxin contamination and
food product inspections were mandated by the China
government; however, aflatoxin exposure continues to be
a major food contaminate in southeast China and, to
lesser extent, throughout China. Limiting recruitment to
hospitals in regions with lower risks for aflatoxin expo-
sures has reduced the confounding impact of environ-
Table 4: Power calculations for the HBV study.
Allele Frequency (n = 400 cases, 400 controls)
Odds Ratio = 1.5 % Power, alpha≤ 0.05
0.01 09
0.05 27
0.1 45
0.2 67
0.5 81
Odds Ratio = 2
0.01 20
0.05 69
0.1 91
0.2 99
0.5 99BMC Infectious Diseases 2008, 8:1 http://www.biomedcentral.com/1471-2334/8/1
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mental dietary factors, and particularly aflatoxin
exposure. Enrollment is also limited to probands and con-
trols who are not co-infected with HCV or HDV viruses to
avoid confounding by these hepatitis viruses known to
interact with HBV. These inclusion and exclusion criteria
are expected to increase specificity by reducing heteroge-
neity due to non-genetic factors.
Patients were stratified according to their infection status
and the severity of their disease using stringent clinical
and laboratory criteria. We anticipate that the identifica-
tion of genetic risk predictors for different specific out-
comes will inform clinical management of persons with
chronic infection and lead to the development of better
therapeutic agents. The identification of genes implicated
in pathways leading to chronic HBV replication, liver
inflammation, fibrosis, and the carcinogenic process will
hopefully lead to improved diagnosis, risk prediction, and
clinical care.
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